Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints

por Petersen, Ronald C., Graf, Ana, Carrillo, Maria C., Weber, Christopher J.
Publicado 2022

Active immunotherapy options for Alzheimer’s disease

por Winblad, Bengt, Graf, Ana, Riviere, Marie-Emmanuelle, Andreasen, Niels, Ryan, J Michael
Publicado 2014

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Dise...

por Nakamura, Yu, Imai, Yukimichi, Shigeta, Masahiro, Graf, Ana, Shirahase, Toru, Kim, Hyosung, Fujii, Akifumi, Mori, Joji, Homma, Akira
Publicado 2011

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

por Farlow, Martin R, Andreasen, Niels, Riviere, Marie-Emmanuelle, Vostiar, Igor, Vitaliti, Alessandra, Sovago, Judit, Caputo, Angelika, Winblad, Bengt, Graf, Ana
Publicado 2015

Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease

por Caputo, Angelika, Racine, Amy, Paule, Ines, Tariot, Pierre N., Langbaum, Jessica B., Coello, Neva, Riviere, Marie-Emmanuelle, Ryan, J. Michael, Lopez, Cristina Lopez, Graf, Ana
Publicado 2023

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

por Vandenberghe, Rik, Riviere, Marie-Emmanuelle, Caputo, Angelika, Sovago, Judit, Maguire, R. Paul, Farlow, Martin, Marotta, Giovanni, Sanchez-Valle, Raquel, Scheltens, Philip, Ryan, J. Michael, Graf, Ana
Publicado 2016

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations

por Petersen, Ronald C., Graf, Ana, Brady, Chris, De Santi, Susan, Florian, Hana, Landen, Jaren, Pontecorvo, Mike, Randolph, Christopher, Sink, Kaycee M., Carrillo, Maria C., Weber, Christopher J.
Publicado 2023

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease

por Langbaum, Jessica B., Ellison, Noel N., Caputo, Angelika, Thomas, Ronald G., Langlois, Carolyn, Riviere, Marie-Emmanuelle, Graf, Ana, Lopez Lopez, Cristina, Reiman, Eric M., Tariot, Pierre N., Hendrix, Suzanne B.
Publicado 2020

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease

por Lopez Lopez, Cristina, Tariot, Pierre N., Caputo, Angelika, Langbaum, Jessica B., Liu, Fonda, Riviere, Marie-Emmanuelle, Langlois, Carolyn, Rouzade-Dominguez, Marie-Laure, Zalesak, Martin, Hendrix, Suzanne, Thomas, Ronald G., Viglietta, Vissia, Lenz, Rob, Ryan, J. Michael, Graf, Ana, Reiman, Eric M.
Publicado 2019

Measuring cognition and function in the preclinical stage of Alzheimer's disease

por Weintraub, Sandra, Carrillo, Maria C., Farias, Sarah Tomaszewski, Goldberg, Terry E., Hendrix, James A., Jaeger, Judith, Knopman, David S., Langbaum, Jessica B., Park, Denise C., Ropacki, Michael T., Sikkes, Sietske A.M., Welsh-Bohmer, Kathleen A., Bain, Lisa J., Brashear, Robert, Budur, Kumar, Graf, Ana, Martenyi, Ferenc, Storck, Marta Segardahl, Randolph, Christopher
Publicado 2018

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease

por Neumann, Ulf, Ufer, Mike, Jacobson, Laura H, Rouzade‐Dominguez, Marie‐Laure, Huledal, Gunilla, Kolly, Carine, Lüönd, Rainer M, Machauer, Rainer, Veenstra, Siem J, Hurth, Konstanze, Rueeger, Heinrich, Tintelnot‐Blomley, Marina, Staufenbiel, Matthias, Shimshek, Derya R, Perrot, Ludovic, Frieauff, Wilfried, Dubost, Valerie, Schiller, Hilmar, Vogg, Barbara, Beltz, Karen, Avrameas, Alexandre, Kretz, Sandrine, Pezous, Nicole, Rondeau, Jean‐Michel, Beckmann, Nicolau, Hartmann, Andreas, Vormfelde, Stefan, David, Olivier J, Galli, Bruno, Ramos, Rita, Graf, Ana, Lopez Lopez, Cristina
Publicado 2018